Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Major Depressive Disorder: full-pipeline trial registry
109 of 283 indexed Major Depressive Disorder trials are currently recruiting.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 109 currently recruiting · #33 of 28,707 conditions by registered trial count
Major Depressive Disorder: 283 US clinical trials tracked, 109 recruiting.
Major Depressive Disorder is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 74 are in Phase 3-4 (later-stage) and 81 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 19 of these trials.
Enrollment posture brief
Registry condition major-depressive-disorder
OPEN 109 | RECR 39% | LATE 74 | EARLY 81 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Major Depressive Disorder lists 109 open slots (39% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Major Depressive Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Major Depressive Disorder recruits in line with its size-band peers.
109 of 283 indexed trials (38.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Major Depressive Disorder trials is spread across many organizations.
Massachusetts General Hospital accounts for 19 of 283 trials (6.7%). 118 distinct sponsors appear on at least one study for this condition label.
-
Typical Major Depressive Disorder enrolment sits around 81 participants.
Median target enrolment is 81 among the 283 trials that report a genuine target (sentinel values excluded). 145 of those (51.2%) plan for fewer than 100 participants.
-
Major Depressive Disorder research is mostly interventional.
258 interventional and 25 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 6 of 6
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
Pfizer
NCT00952653
Brain Imaging of Psychotherapy for Depression
University of North Carolina, Chapel Hill
NCT00609453
Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)
University of California, Los Angeles
NCT01185977
Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder
Stanford University
NCT05525390
Study of Naltrexone-Induced Blockade of Antidepressant Effects
Marta Peciña, MD PhD
NCT04322526
Ketamine for Depression: An MRI Study
Massachusetts General Hospital
NCT02544607
Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
New York State Psychiatric Institute
NCT00521352
Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation
University of Pennsylvania
NCT01492309
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Washington University School of Medicine
NCT02139540
Pilot Decentralized Trial
Alto Neuroscience
NCT05419869
A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
Eli Lilly and Company
NCT01250873
Mechanism of Action of tACS for the Treatment of MDD
University of North Carolina, Chapel Hill
NCT03994081
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Massachusetts General Hospital
NCT01103271
A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care
University of Texas Southwestern Medical Center
NCT00939250
Sertraline vs. Venlafaxine XR
Vanderbilt University
NCT00179283
A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
University of Utah
NCT04504253
Focal Electroconvulsive Therapy for Depression
Medical University of South Carolina
NCT01589315
Dichotic Listening as a Predictor of Medication Response in Depression
New York State Psychiatric Institute
NCT00404755
Ketamine Infusion for Adolescent Depression and Anxiety
Yale University
NCT02579928
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
University of Pittsburgh
NCT02185131
ANC-501 in the Treatment of Adults With Major Depressive Disorder
Ancora Bio, Inc. d/b/a EmbarkNeuro
NCT05439603
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
Perry Renshaw
NCT02356107
Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
Naurex, Inc, an affiliate of Allergan
NCT02366364
TMS for Adults With Autism and Depression
Medical University of South Carolina
NCT02939560
Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
CeNeRx BioPharma
NCT01633437
Burst Suppression Anesthesia for Treatment of Severe Depression
University of Utah
NCT02935647
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
University of Pittsburgh
NCT02646449
Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)
University of Minnesota
NCT06961851
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens
Paul E. Croarkin
NCT01502033
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
Massachusetts General Hospital
NCT00505518
Duloxetine for Perimenopausal Depression
University of Arizona
NCT00517985
Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression
University of Florida
NCT02141776
Dose-Optimized and Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
University of California, San Diego
NCT06730841
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 57 |
| Phase 3 | 45 |
| Phase 4 | 29 |
Top Sponsors
Named interventions
Most-linked intervention names on Major Depressive Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Major Depressive Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Major Depressive Disorder page
283 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 Major Depressive Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Major Depressive Disorder trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Major Depressive Disorder condition card totals 283 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.